|
|
|
|
| LEADER |
02882nam a2200697 4500 |
| 001 |
ocn772774190 |
| 003 |
OCoLC |
| 005 |
20170124070711.4 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
120113s2012 enk ob 001 0 eng |
| 010 |
|
|
|a 2012002010
|
| 040 |
|
|
|a DLC
|b eng
|e pn
|c DLC
|d DG1
|d N$T
|d YDXCP
|d E7B
|d NLGGC
|d NLE
|d CN3GA
|d EBLCP
|d OCLCQ
|d OCLCO
|d OCLCQ
|d DEBBG
|d OCLCQ
|d GrThAP
|
| 019 |
|
|
|a 860515116
|
| 020 |
|
|
|a 9781118301913
|q (MobiPocket)
|
| 020 |
|
|
|a 1118301919
|q (MobiPocket)
|
| 020 |
|
|
|a 9781118302057
|q (Adobe PDF)
|
| 020 |
|
|
|a 1118302052
|q (Adobe PDF)
|
| 020 |
|
|
|a 9781118302064
|q (ePub)
|
| 020 |
|
|
|a 1118302060
|q (ePub)
|
| 020 |
|
|
|a 9781118301906
|q (electronic bk.)
|
| 020 |
|
|
|a 1118301900
|q (electronic bk.)
|
| 020 |
|
|
|z 9781119967262
|q (pbk.)
|
| 029 |
1 |
|
|a AU@
|b 000048454846
|
| 029 |
1 |
|
|a DEBBG
|b BV041069164
|
| 029 |
1 |
|
|a DEBBG
|b BV042795963
|
| 029 |
1 |
|
|a NZ1
|b 15915757
|
| 029 |
1 |
|
|a NZ1
|b 16242848
|
| 029 |
1 |
|
|a DEBBG
|b BV043393977
|
| 035 |
|
|
|a (OCoLC)772774190
|z (OCoLC)860515116
|
| 042 |
|
|
|a pcc
|
| 050 |
0 |
0 |
|a RM301.25
|
| 060 |
1 |
0 |
|a QZ 42
|
| 072 |
|
7 |
|a MED
|x 072000
|2 bisacsh
|
| 082 |
0 |
0 |
|a 615/.4
|2 23
|
| 049 |
|
|
|a MAIN
|
| 100 |
1 |
|
|a Orleans-Lindsay, Justina.
|
| 245 |
1 |
0 |
|a Pharmacovigilance medical writing :
|b a good practice guide /
|c Justina Orleans-Lindsay.
|
| 264 |
|
1 |
|a Chichester, West Sussex, UK :
|b Wiley Blackwell,
|c 2012.
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a Pharmacovigilance medical writing : an overview across the drug development process -- Pharmacovigilance medical writing for clinical trials -- Pharmacovigilance medical writing for CTD submissions -- Pharmacovigilance medical writing in risk evaluation & management -- Pharmacovigilance medical writing for marketed products -- The Ad-Hoc safety review & response to questions document -- The rest of the world.
|
| 588 |
0 |
|
|a Print version record and CIP data provided by publisher.
|
| 650 |
|
0 |
|a Pharmacoepidemiology.
|
| 650 |
|
0 |
|a Writing.
|
| 650 |
|
0 |
|a Drug monitoring.
|
| 650 |
|
0 |
|a Communication in medicine
|x Methodology.
|
| 650 |
|
2 |
|a Pharmacoepidemiology.
|
| 650 |
|
2 |
|a Writing.
|
| 650 |
|
2 |
|a Drug Monitoring.
|
| 650 |
|
2 |
|a Health Communication
|x methods.
|
| 650 |
|
2 |
|a Pharmaceutical Preparations
|x adverse effects.
|
| 650 |
|
2 |
|a Product Surveillance, Postmarketing.
|
| 650 |
|
7 |
|a MEDICAL
|x Pharmacy.
|2 bisacsh
|
| 655 |
|
4 |
|a Electronic books.
|
| 776 |
0 |
8 |
|i Print version:
|a Orleans-Lindsay, Justina.
|t Pharmacovigilance medical writing.
|d Chichester, West Sussex, UK : John Wiley & Sons Inc., 2012
|z 9781119967262
|w (DLC) 2012001218
|
| 856 |
4 |
0 |
|u https://doi.org/10.1002/9781118301906
|z Full Text via HEAL-Link
|
| 994 |
|
|
|a 92
|b DG1
|
